Neoadjuvant Treatment in Resectable Pancreatic Cancer
Status:
Terminated
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
Sequential Neoadjuvant Chemoradiotherapy (CRT) Followed by Curative Surgery vs. Primary
Surgery Alone for Resectable, Non-metastasized Pancreatic Adenocarcinoma
Phase:
Phase 3
Details
Lead Sponsor:
Universitätsklinikum Hamburg-Eppendorf
Collaborators:
Hannover Medical School Heidelberg University Klinikum Augsburg Klinikum Darmstadt Klinikum Stuttgart Ludwig-Maximilians - University of Munich Saarland University SRH Wald-Klinikum Gera GmbH St. Josef Hospital Bochum Staedtisches Klinikum Karlsruhe Technische Universität München Universität des Saarlandes University Hospital Augsburg University Hospital Freiburg University Hospital Regensburg University Hospital Schleswig-Holstein University of Jena University of Rostock University of Schleswig-Holstein